Page last updated: 2024-11-10

tylosin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5280440
CHEMBL ID42743
CHEBI ID17658
SCHEMBL ID3081
SCHEMBL ID16931534
MeSH IDM0023982
PubMed CID45357419
MeSH IDM0023982

Synonyms (88)

Synonym
yef4jxn031 ,
tylosin [usp:inn:ban]
unii-yef4jxn031
tylosin a
tylosinum
tylosine
[(2r,3r,4e,6e,9r,11r,12s,13s,14r)-12-[3,6-dideoxy-4-o-(2,6-dideoxy-3-c-methyl-alpha-l-ribo-hexopyranosyl)-3-(dimethylamino)-beta-d-glucopyranosyloxy]-2-ethyl-14-hydroxy-5,9,13-trimethyl-8,16-dioxo-11-(2-oxoethyl)oxacyclohexadeca-4,6-dien-3-yl]methyl 6-deo
tylocine
CHEBI:17658 ,
tilosina
BSPBIO_003548
C01457
tylan
tylosin (usp/inn)
tylan (tn)
D02490
ai3-29799
tilosina [inn-spanish]
vubityl 200
(10e,12e)-(3r,4s,5s,6r,8r,14s,15r)-14-((6-deoxy-2,3-di-o-methyl-beta-d-allopyranosyl)oxymethyl)-5-((3,6-dideoxy-4-o-(2,6-dideoxy-3-c-methyl-alpha-l-ribo-hexopyranosyl)-3-dimethylamino-beta-d-glucopyranosyl)oxy)-6-formylmethyl-3-hydroxy-4,8,12-trimethyl-9-
antibiotic obtained from cultures of streptomyces fradiae, or the same substance produced by any other means
fradizine
hsdb 7022
einecs 215-754-8
tylosine [inn-french]
tylosinum [inn-latin]
SPECTRUM1505312
LMPK04000004
HMS2093B11
e713
CHEMBL42743
HMS1922B22
2-[(4r,5s,6s,7r,9r,11e,13e,15r,16r)-6-[(2r,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl
nsc758961
pharmakon1600-01505312
CCG-38343
S5108
tylosin [green book]
tylosin [mart.]
tylosin [usp monograph]
tylosin [inn]
tylosin [usp impurity]
tylosin [usp-rs]
tylosin [mi]
WBPYTXDJUQJLPQ-VMXQISHHSA-N
SCHEMBL3081
CS-3442
DTXSID3043996 ,
HY-B0519A
SCHEMBL16931534
AB00959655_03
AB00959655_04
SR-05000002057-3
sr-05000002057
SR-05000002057-2
SR-05000002057-1
2-[(4r,5s,6s,7r,9r,11e,13z,15r,16r)-6-[(2r,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl
8026-48-0
SBI-0206754.P001
[(2r,3r,4e,6e,9r,11r,12s,13s,14r)-12-{[3,6-dideoxy-4-o-(2,6-dideoxy-3-c-methyl-alpha-l-ribo-hexopyranosyl)-3-(dimethylamino)-beta-d-glucopyranosyl]oxy}-2-ethyl-14-hydroxy-5,9,13-trimethyl-8,16-dioxo-11-(2-oxoethyl)oxacyclohexadeca-4,6-dien-3-yl]methyl 6-d
Q411462
DB11475
BRD-K37753391-046-03-2
NCGC00263955-02
tylosin a; fradizine
AKOS037515746
tylosin a 100 microg/ml in acetonitrile
tylosin (usp impurity)
tylosine (inn-french)
tylosinum (inn-latin)
tilosina (inn-spanish)
tylosin (usp:inn:ban)
tylosin (usp-rs)
dtxcid001473373
tylan 50
tylovet 200 mg/ml injection
tylosin (usp monograph)
tylosin (mart.)
tylan 200 injection, tylan 50 injection
((2r,3r,4e,6e,9r,11r,12s,13s,14r)-12-((3,6-dideoxy-4-o-(2,6-dideoxy-3-c-methyl-alpha-l-ribo-hexopyranosyl)-3-(dimethylamino)-beta-d-glucopyranosyl)oxy)-2-ethyl-14-hydroxy-5, 9,13-trimethyl-8, 16-dioxo-11-(2-oxoethyl)oxacyclohexadeca-4,6-dien-3-yl)methyl 6
((2r,3r,4e,6e,9r,11r,12s,13s,14r)-12-(3,6-dideoxy-4-o-(2,6-dideoxy-3-c-methyl-alpha-l-ribo-hexopyranosyl)-3-(dimethylamino)-beta-d-glucopyranosyloxy)-2-ethyl-14-hydroxy-5,9,13-trimethyl-8,16-dioxo-11-(2-oxoethyl)oxacyclohexadeca-4,6-dien-3-yl)methyl 6-deo
tylosinum (latin)
tylosin base
tylan 200
tylosin ,
1401-69-0
AKOS015961863
AC-15162

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" However, administration of L-carnitine could ameliorate these adverse toxic effects of tilmicosin in mice."( The possible protective effect of L-carnitine on tilmicosin-induced cardiotoxicity in mice.
Citil, M; Karapehlivan, M; Kart, A; Yapar, K, 2007
)
0.34
" The high nanoparticle dose induced transient clinical symptoms of treatment effect such as transient reversible action retardation, anorexy and gloomy spirit, increased spleen and liver coefficients and decreased heart coefficients, microscopic pathological changes of liver, spleen and heart, and minor changes in hematologic and biochemical parameters, but no adverse effects were observed in the nanoparticle low dose group."( Acute toxicity study of tilmicosin-loaded hydrogenated castor oil-solid lipid nanoparticles.
Dong, Z; Li, X; Wang, F; Wang, X; Wang, Y; Xie, S; Zhou, W; Zhu, L, 2011
)
0.37
"The results revealed that the LD50 of Til-HCO-SLN and blank HCO-SLN exceeded 5 g/kg."( Acute toxicity study of tilmicosin-loaded hydrogenated castor oil-solid lipid nanoparticles.
Dong, Z; Li, X; Wang, F; Wang, X; Wang, Y; Xie, S; Zhou, W; Zhu, L, 2011
)
0.37
" Population growth rates were assessed via epifluorescent microscopic cell counts, from which the half-max inhibitory concentrations (IC(50)) were calculated and used as part of a toxic unit (TU) method for assessing mixture interactions."( Toxic effect of the combined antibiotics ciprofloxacin, lincomycin, and tylosin on two species of marine diatoms.
Hagenbuch, IM; Pinckney, JL, 2012
)
0.38
" We conclude that myrrh and (or) vitamin C administration minimizes the toxic effects of TIL through their free-radical-scavenging and potent antioxidant activities."( Synergistic protective role of mirazid (Commiphora molmol) and ascorbic acid against tilmicosin-induced cardiotoxicity in mice.
Abdel-Daim, MM; Fayez, M; Ghazy, EW, 2015
)
0.42
"The present study evaluated the toxic effects of Tilmicosin (TIL) on adult rats."( Astragalus polysaccharides alleviate tilmicosin-induced toxicity in rats by inhibiting oxidative damage and modulating the expressions of HSP70, NF-kB and Nrf2/HO-1 pathway.
Ahmed, SYA; Alagawany, M; Elhady, WM; Farag, MR; Taha, HSA, 2019
)
0.51
" Therefore, it is recommended to pay attention to the proper withdrawal periods before marketing to ensure the hygienic suitability of broilers edibles for safe human consumption."( When is it safe to eat different broiler chicken tissues after administration of doxycycline and tylosin mixture?
Fayez, YM; Michael, AM; Monir, HH; Nessim, CK, 2021
)
0.62
" The most frequently reported adverse events were nausea (8/78, 10%) and headache (6/78, 8%)."( A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity.
Alami, N; Carr, RA; Carter, DC; Cohen, DE; Gallenberg, L; Kempf, DJ; Klein, CE; Kwatra, NV; Marsh, KC; Neenan, M; Porcalla, AR; Snodgrass, L; Zhao, W, 2023
)
0.91

Pharmacokinetics

Despite common use of tylosin in turkeys, the pharmacokinetic (PK) data for this drug is limited. A study of a commercial florfenicol-tylosin (2:1) combination product was conducted in six beagle dogs after intravenous and intramuscular administration.

ExcerptReferenceRelevance
" When the pharmacokinetic data was fitted to an allometric model, the logarithms of volume of distribution, clearance, and half-life were linearly related to the logarithms of body weight."( Interspecies correlation of the pharmacokinetics of erythromycin, oleandomycin, and tylosin.
Duthu, GS, 1985
)
0.27
" The elimination half-life (t1/2 beta) values for 3 cows were 46."( Tilmicosin antibacterial activity and pharmacokinetics in cows.
Glickman, A; Saran, A; Shem-Tov, M; Winkler, M; Ziv, G, 1995
)
0.29
"Biological availability and pharmacokinetic properties of tylosin were determined in broiler chickens after oral (p."( Pharmacokinetics of tylosin in broiler chickens.
Kowalski, C; Roliński, Z; Wawron, W; Zań, R, 2002
)
0.31
" Various pharmacokinetic parameters including area under plasma concentration-time curve (AUC(0-72)), maximum plasma concentration (C(max)), time to peak concentration (t(max)), elimination half-life (t(1/2beta)), elimination rate (k(el)), clearance (Cl(B)), mean residence time (MRT) and volume of distribution (V(d,area)) were determined for both formulations."( Pharmacokinetics of tilmicosin (Provitil powder and Pulmotil liquid AC) oral formulations in chickens.
Abu-Basha, EA; Al-Shunnaq, AF; Idkaidek, NM, 2007
)
0.34
" A pharmacokinetic study evaluated the disposition of tilmicosin in the horse after oral (4 mg/kg) or subcutaneous (s."( Pharmacokinetics of tilmicosin in equine tissues and plasma.
Boison, JO; Clark, C; Dowling, PM; Ross, S; Woodbury, M, 2008
)
0.35
"Clinical pharmacokinetic profiles were investigated following intramuscular (i."( Comparative pharmacokinetics of tylosin or florfenicol after a single intramuscular administration at two different doses of tylosin-florfenicol combination in pigs.
Chang, ZQ; Choi, JY; Gebru, E; Hwang, MH; Kang, EH; Kim, MH; Lim, JH; Park, SC; Yun, HI, 2008
)
0.35
"A pharmacokinetic study of a commercial florfenicol-tylosin (2:1) combination product was conducted in six beagle dogs after intravenous (IV) and intramuscular (IM) administration at doses of 10 mg/kg (florfenicol) and 5 mg/kg (tylosin)."( Pharmacokinetics of a florfenicol-tylosin combination after intravenous and intramuscular administration to beagle dogs.
Gebru, E; Kim, EY; Kim, JC; Lee, JS; Park, SC, 2011
)
0.37
"The intravenous pharmacokinetic profile of tilmicosin is yet to be achieved because of the cardiovascular effects of tilmicosin."( Pharmacokinetics of tilmicosin in beef cattle following intravenous and subcutaneous administration.
Hassfurther, R; Hunter, RP; Lombardi, KR; Portillo, T, 2011
)
0.37
" Mean residence time from the time of dosing to the time of last measurable concentration (MRT(last)) and terminal half-life (T(1/2) ) was 6 and 9 days, respectively."( Pharmacokinetics of tildipirosin in bovine plasma, lung tissue, and bronchial fluid (from live, nonanesthetized cattle).
Allan, M; Bohland, C; Kilp, S; Menge, M; Metz, W; Nürnberger, M; Röpke, R; Rose, M; Zschiesche, E, 2012
)
0.38
" Mean residence time from the time of dosing to the time of last measurable concentration (MRTlast) and terminal half-life (T1/2) both were about 4 days."( Pharmacokinetics of tildipirosin in porcine plasma, lung tissue, and bronchial fluid and effects of test conditions on in vitro activity against reference strains and field isolates of Actinobacillus pleuropneumoniae.
Allan, M; Bohland, C; Kilp, S; Menge, M; Metz, W; Nürnberger, M; Röpke, R; Rose, M; Wilhelm, C; Zschiesche, E, 2013
)
0.39
"The interaction between bentonite and tylosin was investigated in broiler chickens, based on pharmacokinetic characteristics obtained in vivo."( Interaction between tylosin and bentonite clay from a pharmacokinetic perspective.
Croubels, S; De Backer, P; De Baere, S; Devreese, M; Goossens, J; Osselaere, A; Vandenbroucke, V, 2012
)
0.38
" After oral administration, there were significant differences in the Cmax (0."( Comparative pharmacokinetics and bioavailability of tylosin tartrate and tylosin phosphate after a single oral and i.v. administration in chickens.
Ding, RL; Dong, LL; Feng, XW; Ji, H; Ji, LW; Jiang, SX; Li, D, 2014
)
0.4
"23 µg/mL, the time required to reach the peak concentration (t max) was found to be 2nd and 4th h, and elimination half-lives (t 1/2β ) were found to be 20."( Milk and blood pharmacokinetics of tylosin and tilmicosin following parenteral administrations to cows.
Avci, T; Elmas, M, 2014
)
0.4
"Despite common use of tylosin in turkeys, the pharmacokinetic (PK) data for this drug in turkeys is limited."( Allometric analysis of tylosin tartrate pharmacokinetics in growing male turkeys.
Bobrek, K; Motykiewicz-Pers, K; Poźniak, B; Świtała, M; Tikhomirov, M, 2020
)
0.56
" Finally, a pharmacokinetic study was performed."( Preparation, characterization, and pharmacokinetics of tilmicosin taste-masked formulation via hot-melt extrusion technology.
Deng, R; Deng, X; Feng, X; He, J; Ji, M; Liang, Q; Lv, L; Peng, J; Wen, X; Wu, L; Yan, G, 2020
)
0.56
" Two animal experiments with a total of 12 minks were conducted to study the serum pharmacokinetic (PK) characteristics of TYL in mink after 10 mg/kg IV and oral dosing, respectively."( Evaluating a tylosin dosage regimen for treatment of Staphylococcus delphini infection in mink (Neovison vison): a pharmacokinetic-pharmacodynamic approach.
Birch, JM; Damborg, P; Frandsen, HL; Ronaghinia, AA; Struve, T; Toutain, PL, 2021
)
0.62
"Maximum concentrations (Cmax) of flubentylosin were reached after 1-2 hours, with a half-life < 4 hours at doses ≤ 400 mg."( A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity.
Alami, N; Carr, RA; Carter, DC; Cohen, DE; Gallenberg, L; Kempf, DJ; Klein, CE; Kwatra, NV; Marsh, KC; Neenan, M; Porcalla, AR; Snodgrass, L; Zhao, W, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" Left ventricular function, systemic arterial blood pressure, and heart rate (HR) responses to TM alone and in combination with propranolol(P) or dobutamine HCl(DOB) were evaluated."( Cardiovascular effects of the macrolide antibiotic tilmicosin, administered alone and in combination with propranolol or dobutamine, in conscious unrestrained dogs.
Main, BW; Means, JR; Rinkema, LE; Sarazan, RD; Smith, WC, 1996
)
0.29
"The objective of this research was to use data from multiple studies to comprehensively quantify the effects of feeding 1) laidlomycin propionate (LP), alone and/or in combination with chlortetracycline, compared with 2) monensin sodium (MS), alone and/or in combination with tylosin, at commercially approved dosages, on ADG, DMI, feed efficiency (FE), mortality, and carcass characteristics (HCW and liver abscesses)."( Meta-analysis of the effects of laidlomycin propionate, fed alone or in combination with chlortetracycline, compared with monensin sodium, fed alone or in combination with tylosin, on growth performance, health, and carcass outcomes in finishing steers in
Branine, M; Cernicchiaro, N; Corbin, M; Prouty, F; Quinn, M; Renter, DG, 2016
)
0.43
" Despite that, little is comprehended about influences of the drug-drug interactions (DDIs) caused by EF and TIM."( A new drug-drug interaction-tilmicosin reduces the metabolism of enrofloxacin through CYP3A4.
Badawy, S; Liu, Z; Tao, Y; Wang, L; Wang, X; Xie, C; Zhang, L, 2022
)
0.72

Bioavailability

Tylosin is a hydrosoluble compound, with a molecular weight of 916 g/mol. It has a low oral bioavailability and a low apparent volume of distribution. The systemic bioavailability of tylosin injected intramuscularly was 72.

ExcerptReferenceRelevance
" Evaluation of in vitro and in vivo antimicrobial activity indicated that derivatives of demycarosyltylosin (desmycosin) combined the broadest spectrum of antimicrobial activity with the best efficacy and bioavailability after oral administration."( Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
Counter, FT; Debono, M; Felty-Duckworth, AM; Kirst, HA; Ott, JL; Pekarek, RS; Toth, JE; Truedell, BA; Willard, KE, 1988
)
0.79
" The systemic bioavailability of tylosin injected intramuscularly was 72."( Disposition of tylosin in goats.
Atef, M; Atta, AH; el-Maaz, AA; Youssef, SA, 1991
)
0.28
" The systemic bioavailability of tylosin injected intramuscularly was 72."( Disposition of tylosin in goats.
Atef, M; Atta, AH; el-Maaz, AA; Youssef, SA,
)
0.13
" multocida in experimental infections in chicks; and 3) bioavailability after oral administration to laboratory animals."( Structure-activity studies of 20-deoxo-20-amino derivatives of tylosin-related macrolides.
Counter, FT; Debono, M; Felty-Duckworth, AM; Kirst, HA; Leeds, JP; Ose, EE; Ott, JL; Toth, JE; Truedell, BA; Willard, KE, 1989
)
0.28
" Certain 20-modified derivatives of desmycosin demonstrated good oral bioavailability in chicks and a lead compound with oral efficacy in the Pasteurella infection model was discovered."( In vitro and in vivo evaluation of C-20- and C-23-modified derivatives of tylosin against veterinary pathogens.
Debono, M; Felty-Duckworth, AM; Kirst, HA; Ose, EE; Pekarek, RS; Toth, JE; Willard, KE, 1988
)
0.27
" bioavailability was 22%."( Tilmicosin antibacterial activity and pharmacokinetics in cows.
Glickman, A; Saran, A; Shem-Tov, M; Winkler, M; Ziv, G, 1995
)
0.29
" The bioavailability (f) of the drug in goats (0."( Disposition kinetics of tylosin administered intravenously and intramuscularly in desert sheep and Nubian goats.
Abdullah, AS; Elsheikh, HA; Khalafalla, AE; Osman, IA; Taha, AA, 1999
)
0.3
" This may reduce the bioavailability and thus biodegradation rates of TYL."( Biodegradability of metronidazole, olaquindox, and tylosin and formation of tylosin degradation products in aerobic soil--manure slurries.
Halling-Sørensen, B; Ingerslev, F, 2001
)
0.31
"7 min and bioavailability was 95%."( Disposition kinetics of tylosin administered intravenously and intramuscularly to pigs.
Arboix, M; El Korchi, G; Francesch, R; Pérez, B; Prats, C, 2002
)
0.31
"A bioavailability and pharmacokinetics study of powder and liquid tilmicosin formulations was carried out in 18 healthy chickens according to a single-dose, two-period, two-sequence, crossover randomized design."( Pharmacokinetics of tilmicosin (Provitil powder and Pulmotil liquid AC) oral formulations in chickens.
Abu-Basha, EA; Al-Shunnaq, AF; Idkaidek, NM, 2007
)
0.34
" These compounds are poorly absorbed during digestion so that the bioactive compound or metabolites are excreted."( Effect of antimicrobial compounds tylosin and chlortetracycline during batch anaerobic swine manure digestion.
Clay, SA; Porath, LR; Spellman, GM; Stone, JJ; Wong, KL; Zhu, Z, 2009
)
0.35
" administration, the absorption half-life and the corresponding t(max) revealed rapid absorption rate with systemic bioavailability (F%) of 76."( Effect of albendazole administration on pharmacokinetic aspects of tylosin in lactating goats.
Atef, M; Darwish, AS; Fahim, AM; Ramadan, A, 2009
)
0.35
" A rapid and nearly complete absorption of both drugs with a mean IM bioavailability of 103."( Pharmacokinetics of a florfenicol-tylosin combination after intravenous and intramuscular administration to beagle dogs.
Gebru, E; Kim, EY; Kim, JC; Lee, JS; Park, SC, 2011
)
0.37
" The data from the two different studies were used to calculate bioavailability values, which support the assumption that tilmicosin is 100% bioavailable in cattle."( Pharmacokinetics of tilmicosin in beef cattle following intravenous and subcutaneous administration.
Hassfurther, R; Hunter, RP; Lombardi, KR; Portillo, T, 2011
)
0.37
" Absolute bioavailability was 78."( Pharmacokinetics of tildipirosin in bovine plasma, lung tissue, and bronchial fluid (from live, nonanesthetized cattle).
Allan, M; Bohland, C; Kilp, S; Menge, M; Metz, W; Nürnberger, M; Röpke, R; Rose, M; Zschiesche, E, 2012
)
0.38
"The pharmacokinetics and oral bioavailability of tylosin tartrate and tylosin phosphate were carried out in broiler chickens according to a principle of single dose, random, parallel design."( Comparative pharmacokinetics and bioavailability of tylosin tartrate and tylosin phosphate after a single oral and i.v. administration in chickens.
Ding, RL; Dong, LL; Feng, XW; Ji, H; Ji, LW; Jiang, SX; Li, D, 2014
)
0.4
" Tylosin, a hydrosoluble compound, with a molecular weight of 916 g/mol, has a low oral bioavailability and a low apparent volume of distribution, too."( Withdrawal times of oxytetracycline and tylosin in eggs of laying hens after oral administration.
Araya-Jordán, C; Cornejo, J; Iragüen, D; Maddaleno, A; Muñoz, R; Pizarro, N; San Martín, B, 2014
)
0.4
" The simultaneous administration of coccidiostats and/or antimicrobials with mycotoxin binders might lead to a reduced oral bioavailability of these veterinary medicinal products."( Influence of mycotoxin binders on the oral bioavailability of tylosin, doxycycline, diclazuril, and salinomycin in fed broiler chickens.
Croubels, S; De Backer, P; De Mil, T; De Saeger, S; Devreese, M; Maes, A, 2017
)
0.46
" Furthermore, TMS-NLCs showed higher oral bioavailability in piglets compared to the API suspension."( Nanostructured lipid carriers with exceptional gastrointestinal stability and inhibition of P-gp efflux for improved oral delivery of tilmicosin.
Gao, X; Guo, D; Ji, H; Jiang, S; Li, X; Peng, L; Sahito, B; Wang, L; Yang, H; Zhang, Q, 2020
)
0.56
" NLCs could enhance oral absorption of TMS compared to 10% tilmicosin phosphate solution in broilers, among which the TMS-sNLCs were the most efficient drug delivery carriers, with a relative oral bioavailability of 203."( Synthesis of Tilmicosin Nanostructured Lipid Carriers for Improved Oral Delivery in Broilers: Physiochemical Characterization and Cellular Permeation.
Gao, X; Guo, D; Jiang, S; Kashif, J; Peng, L; Sahito, B; Ul Aabdin, Z; Wang, L; Yang, H; Zhang, Q, 2020
)
0.56
" Bioavailability was variable (5."( Allometric analysis of tylosin tartrate pharmacokinetics in growing male turkeys.
Bobrek, K; Motykiewicz-Pers, K; Poźniak, B; Świtała, M; Tikhomirov, M, 2020
)
0.56

Dosage Studied

Administration of erythromycin, tilmicosin, and tylosin at the label dosage increased abomasal emptying rate in calves. The Tylosin resistance genes and some generic bacteria may exhibited a hormetic-like dose-response.

ExcerptRelevanceReference
"During a total period of treatment of 141 days, divided into starter grower and fattening period, the efficacy of avilamycin in a dosage of 80 mg/kg (starter grower) and 20 mg/kg (fattening) rsp."( [The nutritive effect of avilamycin in swine breeding and fattening].
Dzapo, V; Reiner, G, 1991
)
0.28
" The proportion of each species among the enterococcal population changed with time in birds not dosed with antibiotics."( The effect of ampicillin and tylosin on the faecal enterococci of healthy young chickens.
Hinton, M; Kaukas, A; Linton, AH, 1987
)
0.27
"A method is described for the determination of the factors in tylosin base and tylosin tartrate as raw materials and in dosage forms."( Pharmacopoeial procedure for the determination of tylosin factors by high-performance liquid chromatography.
Carr, GP; Fish, BJ, 1986
)
0.27
"To determine the effective dosage of tilmicosin phosphate when fed to pigs for the control of pneumonia attributable to Actinobacillus pleuropneumoniae."( Efficacy dose determination study of tilmicosin phosphate in feed for control of pneumonia caused by Actinobacillus pleuropneumoniae in swine.
Lechtenberg, KF; Moore, GM; Mowrey, DH; Schneider, JH; Tonkinson, LV, 1996
)
0.29
" The method was tested on milk from a cow dosed with tilmicosin."( Determination of tilmicosin in bovine milk by liquid chromatography with ultraviolet detection.
Ngoh, MA,
)
0.13
"0 mg/kg) were administered to complete a dose-response curve."( Cardiovascular effects of the macrolide antibiotic tilmicosin, administered alone and in combination with propranolol or dobutamine, in conscious unrestrained dogs.
Main, BW; Means, JR; Rinkema, LE; Sarazan, RD; Smith, WC, 1996
)
0.29
" No negative colony effects were noted at any dosage rates."( Laboratory and field studies on the effects of the antibiotic tylosin on honey bee Apis mellifera L. (Hymenoptera: Apidae) development and prevention of American foulbrood disease.
Cheng, P; Fong, A; Montague, MA; Mussen, E; Peng, CY; Wong, G, 1996
)
0.29
" Two groups of challenge-exposed pigs were dosed orally with tylosin phosphate via a 2% stabilized premix, starting with 100 or 40 ppm 4 days before challenge exposure and continuing for 16 days, when the dose was reduced to 40 or 20 ppm, respectively, which was continued for 12 more days."( Oral administration of tylosin phosphate for treatment and prevention of proliferative enteropathy in pigs.
Kroger, HW; Lawrence, K; McOrist, S; Morgan, J; Veenhuizen, MF, 1997
)
0.3
"Tylosin phosphate can be effective for prevention and for treatment of PE, using reported dosing schedules."( Oral administration of tylosin phosphate for treatment and prevention of proliferative enteropathy in pigs.
Kroger, HW; Lawrence, K; McOrist, S; Morgan, J; Veenhuizen, MF, 1997
)
0.3
" route, identical intravenous and intramuscular dosage regimens of tylosin may be recommended for the two species."( Disposition kinetics of tylosin administered intravenously and intramuscularly in desert sheep and Nubian goats.
Abdullah, AS; Elsheikh, HA; Khalafalla, AE; Osman, IA; Taha, AA, 1999
)
0.3
"When intermittent dosing is used during treatment, the concentrations of antibiotics fluctuate and subinhibitory concentrations may occur between doses."( Postantibiotic effects and postantibiotic sub-MIC effects of erythromycin, roxithromycin, tilmicosin, and tylosin on Pasteurella multocida.
Lim, J; Yun, H, 2001
)
0.31
" However, as the present study did not show considerable differences in the pharmacokinetics of tylosin in buffaloes and cattle, similar dosage regimes of this drug can be recommended for both species."( Some comparative aspects of the pharmacokinetics of tylosin in buffaloes and cattle.
Baroni, E; Boggio, JC; Rubio, M; San, AM; Sánchez, S; Saurit, AR, 2002
)
0.31
"Three studies were conducted to determine and confirm the effective dosage rate of ceftiofur crystalline-free acid sterile suspension (CCFA-SS, 200 mg ceftiofur equivalents [CE]/ml), a long-acting ceftiofur formulation, for control and treatment of bovine respiratory disease (BRD)."( Dose determination and confirmation for ceftiofur crystalline-free acid administered in the posterior aspect of the ear for control and treatment of bovine respiratory disease.
Bryson, WL; Chester, ST; Dame, KJ; Hibbard, B; Moseley, WW; Robb, EJ, 2002
)
0.31
"2 micrograms/ml after oral administration of tylosin shows that dosing of this antibiotic in broiler chickens should be higher than in other food producing animals."( Pharmacokinetics of tylosin in broiler chickens.
Kowalski, C; Roliński, Z; Wawron, W; Zań, R, 2002
)
0.31
" On d 21, rumens were dosed 2 h after the morning feeding with 350 g of solubilized casein to evaluate in vivo ruminal protease and deaminase activities."( Effects of virginiamycin and monensin plus tylosin on ruminal protein metabolism in steers fed corn-based finishing diets with or without wet corn gluten feed.
Bindel, DJ; del Barrio, A; Hollis, LC; Ives, SE; Nagaraja, TG; Titgemeyer, EC, 2002
)
0.31
" Residue depletion of tilmicosin in broiler chickens was examined after dosing over a 5-day period by incorporation of the drug into drinking water at 37."( Residue depletion of tilmicosin in chicken tissues.
Fu, C; Guo, J; Jiang, H; Jin, X; Shen, J; Shen, Z; Zhang, Y, 2004
)
0.32
" Such limit has been established according to the lowest dosage of additives still able to elicit an appreciable growth promoting effect."( Identification and quantification method of spiramycin and tylosin in feedingstuffs with HPLC-UV/DAD at 1 ppm level.
Ballerini, A; Brambilla, G; Civitareale, C; Fiori, M, 2004
)
0.32
" Anaerobic microcosms, prepared from freshly collected lagoon slurries, were amended with individual antibiotics at 10 mg/L for the initial screening study and at 1, 5, and 25 mg/L for the dose-response study."( Inhibition of microbial metabolism in anaerobic lagoons by selected sulfonamides, tetracyclines, lincomycin, and tylosin tartrate.
Adams, CD; Henny, C; Loftin, KA; Mormile, MR; Surampali, R, 2005
)
0.33
" No negative effects in colonies were noted at any dosage rates or forms of application."( In vitro and in vivo susceptibility of the honeybee bacterial pathogen Paenibacillus larvae subsp. larvae to the antibiotic tylosin.
Albo, GN; Alippi, AM; De Giusti, MR; Reynaldi, FJ, 2005
)
0.33
"0 mg kg(-1) established according to the reported lowest dosage of additive needed to lead a growth promoting effect."( Sample preparation strategy for the simultaneous determination of macrolide antibiotics in animal feedingstuffs by liquid chromatography with electrochemical detection (HPLC-ECD).
González de la Huebra, MJ; Vincent, U; von Holst, C, 2007
)
0.34
"Administration of erythromycin, tilmicosin, and tylosin at the label dosage increased abomasal emptying rate in calves."( Effect of parenteral administration of erythromycin, tilmicosin, and tylosin on abomasal emptying rate in suckling calves.
Constable, PD; Nouri, M, 2007
)
0.34
" did not appear to be influenced by dosing treatment including the control."( Effect of antimicrobial dosage regimen on Salmonella and Escherichia coli isolates from feeder swine.
Dargatz, DA; Fedorka-Cray, PJ; Straw, BE; Wagner, BA, 2008
)
0.35
" Direct inhibition of the bacterial growth rates, resulting in a dose-response curve, was found above 50 mg of tylosin kg(-1) of soil two days after tylosin addition (IC50 value of 960 mg tylosin kg(-1))."( No long-term persistence of bacterial pollution-induced community tolerance in tylosin-polluted soil.
Bååth, E; Demoling, LA, 2008
)
0.35
"Tilmicosin is a veterinary antibiotic with significant human toxicity at doses commonly used in animals, but the parenteral dose-response relationship has not been well characterized."( American association of poison control centers database characterization of human tilmicosin exposures, 2001-2005.
Oakes, J; Seifert, S, 2008
)
0.35
" A dose-response relationship could be demonstrated."( American association of poison control centers database characterization of human tilmicosin exposures, 2001-2005.
Oakes, J; Seifert, S, 2008
)
0.35
"5 times of the clinic dosage and below the median lethal dose (LD(50)) was subcutaneously administered twice on the first and 7th day."( Acute toxicity study of tilmicosin-loaded hydrogenated castor oil-solid lipid nanoparticles.
Dong, Z; Li, X; Wang, F; Wang, X; Wang, Y; Xie, S; Zhou, W; Zhu, L, 2011
)
0.37
" Normal clinic dosage of Til-HCO-SLN is safe as evaluated by acute toxicity."( Acute toxicity study of tilmicosin-loaded hydrogenated castor oil-solid lipid nanoparticles.
Dong, Z; Li, X; Wang, F; Wang, X; Wang, Y; Xie, S; Zhou, W; Zhu, L, 2011
)
0.37
" Mean residence time from the time of dosing to the time of last measurable concentration (MRT(last)) and terminal half-life (T(1/2) ) was 6 and 9 days, respectively."( Pharmacokinetics of tildipirosin in bovine plasma, lung tissue, and bronchial fluid (from live, nonanesthetized cattle).
Allan, M; Bohland, C; Kilp, S; Menge, M; Metz, W; Nürnberger, M; Röpke, R; Rose, M; Zschiesche, E, 2012
)
0.38
" Mean residence time from the time of dosing to the time of last measurable concentration (MRTlast) and terminal half-life (T1/2) both were about 4 days."( Pharmacokinetics of tildipirosin in porcine plasma, lung tissue, and bronchial fluid and effects of test conditions on in vitro activity against reference strains and field isolates of Actinobacillus pleuropneumoniae.
Allan, M; Bohland, C; Kilp, S; Menge, M; Metz, W; Nürnberger, M; Röpke, R; Rose, M; Wilhelm, C; Zschiesche, E, 2013
)
0.39
" Dosing to achieve MPC concentrations (where possible) may serve to reduce the selection of bacterial subpopulations with reduced antimicrobial susceptibility."( Comparative minimum inhibitory and mutant prevention drug concentrations of enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin against bovine clinical isolates of Mannheimia haemolytica.
Blondeau, BJ; Blondeau, JM; Blondeau, LD; Borsos, S; Hesje, CE, 2012
)
0.38
" None of the three suspensions were cytotoxic at clinical dosage levels."( Preparation and evaluation of tilmicosin-loaded hydrogenated castor oil nanoparticle suspensions of different particle sizes.
Chen, X; Lu, M; Wang, T; Wang, Y; Zhou, W; Zhu, L, 2014
)
0.4
"Despite its wide acceptance as a treatment for canine chronic enteropathies, the macrolide antibiotic tylosin lacks official oral dosage recommendations."( Efficacy of two low-dose oral tylosin regimens in controlling the relapse of diarrhea in dogs with tylosin-responsive diarrhea: a prospective, single-blinded, two-arm parallel, clinical field trial.
Kilpinen, S; Spillmann, T; Westermarck, E, 2014
)
0.4
" The mean fecal consistency scores at the 25 mg/kg tylosin dosage were no significantly different from scores at the 5 mg/kg or 15 mg/kg tylosin dosages (P=0."( Efficacy of two low-dose oral tylosin regimens in controlling the relapse of diarrhea in dogs with tylosin-responsive diarrhea: a prospective, single-blinded, two-arm parallel, clinical field trial.
Kilpinen, S; Spillmann, T; Westermarck, E, 2014
)
0.4
" These results show that the effect of antibiotics on the swine gut microbiota is variable based on dosage and duration and that the swine gut microbiota exhibits considerable resilience to long-term changes due to antibiotic perturbations."( Temporal changes and the effect of subtherapeutic concentrations of antibiotics in the gut microbiota of swine.
Chénier, MR; Holman, DB, 2014
)
0.4
" The 4 medicinal products were dosed using a single bolus administration directly in the crop."( Influence of mycotoxin binders on the oral bioavailability of tylosin, doxycycline, diclazuril, and salinomycin in fed broiler chickens.
Croubels, S; De Backer, P; De Mil, T; De Saeger, S; Devreese, M; Maes, A, 2017
)
0.46
" MPC concentrations provide a dosing target which may serve to reduce amplification of bacterial subpopulations with reduced antimicrobial susceptibility."( Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
Blondeau, JM; Fitch, SD, 2019
)
0.51
"Age has a significant impact on tylosin PK in turkeys and dosage adjustment may be needed, particularly in young individuals."( Allometric analysis of tylosin tartrate pharmacokinetics in growing male turkeys.
Bobrek, K; Motykiewicz-Pers, K; Poźniak, B; Świtała, M; Tikhomirov, M, 2020
)
0.56
" Furthermore, the tylosin resistance genes and some generic bacteria may exhibited a hormetic-like dose-response with the high-dosage inhibition and low dosage stimulation induced by bioavailable Zn contents during the co-composting process, which represented a beneficial aspect of adaptive responses to harmful environmental stimuli."( Insights into the effects of Zn exposure on the fate of tylosin resistance genes and dynamics of microbial community during co-composting with tylosin fermentation dregs and swine manure.
Liu, H; Sun, R; Wang, MM; Wang, P; Yuan, Q; Zhang, B, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
macrolide antibioticA macrocyclic lactone with a ring of twelve or more members which exhibits antibiotic activity.
aldehydeA compound RC(=O)H, in which a carbonyl group is bonded to one hydrogen atom and to one R group.
disaccharide derivativeA carbohydrate derivative that is formally obtained from a disaccharide.
enoneAn alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position.
leucomycin
monosaccharide derivativeA carbohydrate derivative that is formally obtained from a monosaccharide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (207)

Assay IDTitleYearJournalArticle
AID520740Antimicrobial activity against erm(B)-deficient Staphylococcus aureus RN4220 harboring cfr gene by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors.
AID1873912Antibacterial activity against Staphylococcus chromogenes incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID261791Antibacterial activity against macrolide resistant Staphylococcus aureus ATCC BAA-392006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.
AID206101In vitro antimicrobial activity against aerobic bacteria Streptococcus B 81988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID1873908Antibacterial activity against Cronobacter sakazakii ATCC 29544 incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID206931In vitro antimicrobial activity against aerobic bacteria Staphylococcus aureus V1351988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID26629Dissociation constant (pKa)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID127945Peripheral plasma levels in mice after oral administration of 100 mg/kg dose for 4 hr; No detectable concentration of antibiotic1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID396001Antimicrobial activity against Mycoplasma putrefaciens Jordanian isolates after 24 hrs by twofold serial dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibilities of Mycoplasma putrefaciens field isolates.
AID1873904Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs in absence of foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID278990Antibacterial activity against Pseudomonas sp. B13 GFP1 containing macrolide resistance plasmid pRSB1112007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Novel macrolide resistance module carried by the IncP-1beta resistance plasmid pRSB111, isolated from a wastewater treatment plant.
AID571501Antimicrobial activity against Campylobacter jejuni DC2 infected in 15 days old chicken by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Development, stability, and molecular mechanisms of macrolide resistance in Campylobacter jejuni.
AID1873892Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 16 to 20 hrs using 10^3 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID174477Peripheral plasma levels in rats after oral administration of 100 mg/kg dose for 1 hr; No detectable concentration of antibiotic1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID206929In vitro antimicrobial activity against Staphylococcus aureus X11988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID283558Antibacterial activity against Escherichia coli AG102 with marR1 mutation after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID127932Peripheral plasma levels in mice after oral administration of 100 mg/kg dose for 0.25 hr; No detectable concentration of antibiotic1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID261795Antibacterial activity against Enterococcus faecalis ATCC 515752006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.
AID510750Antibacterial activity against Escherichia coli AG102MB harboring pS1328-based acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID41267In vitro antimicrobial activity against anaerobic bacteria bacteroides fragilis 1936B,1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID529877Antimicrobial activity against Escherichia coli AG100A harboring empty vector by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene.
AID283560Antibacterial activity against Escherichia coli HNCE4 after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID157383In vitro antimicrobial activity against anaerobic bacteria peptostreptococcus intermedius 12641988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID523012Ratio of Kcat to Km for macrolide 2'-phosphotransferase 1 by PK/LDH-coupled assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Nucleotide selectivity of antibiotic kinases.
AID209096Effective dose against Streptococcus pyogenes administered orally1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID520732Antimicrobial activity against Staphylococcus aureus RN4220 harboring plasmid LI50 by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors.
AID1873894Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs using 10^7 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873913Antibacterial activity against Escherichia coli incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID261786Antibacterial activity against macrolide resistant Streptococcus pneumoniae ATCC 7009062006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.
AID51134In vitro antimicrobial activity against anaerobic bacteria clostridium septicum 11281988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID571496Antimicrobial activity against Campylobacter jejuni DC2 infected in chicken assessed as microbial shedding level after compound administration through feed for 20 days2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Development, stability, and molecular mechanisms of macrolide resistance in Campylobacter jejuni.
AID510748Antibacterial activity against Escherichia coli AG102MB harboring naive acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID103662Minimum inhibitory concentration measured against Mycoplasma gallisepticum K514 in the presence of extra copper1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and copper-dependent antimycoplasmal activity of amides and amidines derived from 2-amino-1,10-phenanthroline.
AID209110In vivo effective dose against experimental infections in rodent caused by Streptococcus pyogenes C203 when administered sc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID529874Antimicrobial activity against Enterococcus faecalis JH2-2 harboring pAT392 containing rdmC-like gene by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene.
AID207310Antibacterial activity against Staphylococcus aureus PSCB-05382004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Semisynthetic macrolide antibacterials derived from tylosin. Synthesis and structure-activity relationships of novel desmycosin analogues.
AID52544In vitro antimicrobial activity against chlamydia trachomatis.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID278989Antibacterial activity against Pseudomonas sp. B13 GFP1 containing multiresistance plasmid pRSB1012007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Novel macrolide resistance module carried by the IncP-1beta resistance plasmid pRSB111, isolated from a wastewater treatment plant.
AID206104In vitro antimicrobial activity against aerobic bacteria Streptococcus D 80431988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID1424070In-vitro inhibition of protein translation using pY71-sfGFP in PUREexpress in vitro protein synthesis system assessed as reduction in cell-free GFP protein translation at 50 uM measured every 20 mins for 2 hrs2017Journal of natural products, 04-28, Volume: 80, Issue:4
The Berkeleylactones, Antibiotic Macrolides from Fungal Coculture.
AID40788Minimum inhibitory concentration (MIC) required to inhibit the growth of Bacillus subtilis PCI 219 by using nutrient agar as growth medium1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Novel dimeric derivatives of leucomycins and tylosin, sixteen-membered macrolides.
AID21658Calculated partition coefficient (clogP)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID1873945Antibacterial activity against Staphylococcus aureus ATCC 29213 at pH 8.6 incubated for 16 to 20 hrs in presence of 5% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1586841Induction of read through activity at cricket paralysis virus-internal ribosome entry site codon UGG assessed as increase in octapeptide formation from FKVRQ-tRNAGln at 30 to 600 uM measured after 20 mins in presence of Typ-tRNA, Leu-tRNA and [35S]-Met-tR2018ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12
New
AID41411In vitro antimicrobial activity against anaerobic bacteria bacteroides melaninogenicus 1856,1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID127954Peripheral plasma levels in mice after oral administration of 50 mg/kg dose for 1 hr; No detectable concentration of antibiotic1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID24865The negative logarithm of the fraction of singly charged molecules.1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID174471Peripheral plasma levels in rats after oral administration of 100 mg/kg dose for 0.25 hr; No detectable concentration of antibiotic1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID207183Antibacterial activity against Staphylococcus aureus ATCC 137092004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Semisynthetic macrolide antibacterials derived from tylosin. Synthesis and structure-activity relationships of novel desmycosin analogues.
AID155774Minimum inhibitory concentration required to inhibit Pasteurella multocida 59A006 in vitro1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Repromicin derivatives with potent antibacterial activity against Pasteurella multocida.
AID86122In vitro antimicrobial activity against Haemophilus influenzae.1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID50849In vitro antimicrobial activity against anaerobic bacteria Clostridium difficile 29941988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID529867Antimicrobial activity against Streptococcus uberis UCN61 by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene.
AID209613In vitro antimicrobial activity against Staphylococcus pyogenes C2031988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID128090Peripheral plasma levels in mice after oral administration of 50 mg/kg dose for 2 hr; No detectable concentration of antibiotic1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID1873893Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs using 10^6 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID209275Antimicrobial activity against Streptococcus pyogenes C2031988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID529875Antimicrobial activity against Enterococcus faecalis JH2-2 harboring pAT392 containing mph(B) gene by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene.
AID70787Inhibition of 10,11,12,13-[3H]tetrahydroleucomycin A3 binding to Escherichia coli Ribosome1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Novel dimeric derivatives of leucomycins and tylosin, sixteen-membered macrolides.
AID23733Calculated partition coefficient (clogP)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID209064In vitro antimicrobial activity against Streptococcus faecium X661988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID209266Antibacterial activity against Streptococcus pyogenes PSCB-05432004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Semisynthetic macrolide antibacterials derived from tylosin. Synthesis and structure-activity relationships of novel desmycosin analogues.
AID86126In vitro antimicrobial activity against aerobic bacteria Haemophilus influenzae MX366,1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID396002Antimicrobial activity against Mycoplasma putrefaciens KS1 after 24 hrs by twofold serial dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibilities of Mycoplasma putrefaciens field isolates.
AID157245In vitro antimicrobial activity against anaerobic bacteria peptococcus asaccharolyticus 13021988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID261788Antibacterial activity against Staphylococcus aureus ATCC 6538p2006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.
AID1873942Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs in presence of 25% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873940Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs in presence of 5% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID103664The anti-mycoplasmal activity was determined against Mycoplasma gallisepticum K514 with the addition of copper (40 uM CuSO4)1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Synthesis and copper-dependent antimycoplasmal activity of 1-amino-3-(2-pyridyl)isoquinoline derivatives. 2. Amidines.
AID520735Antimicrobial activity against Staphylococcus aureus RN4220 harboring erm(B) and cfr gene by disk diffusion assay2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors.
AID41265In vitro antimicrobial activity against anaerobic bacteria bacteroides fragilis 1111988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID157260In vitro antimicrobial activity against anaerobic bacteria eubacterium peptostreptococcus anaerobius 1428,1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID261783Antibacterial activity against macrolide resistant Streptococcus pneumoniae ATCC 7006762006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.
AID571502Antimicrobial activity against Campylobacter jejuni DC2 infected in 3 days old chicken by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Development, stability, and molecular mechanisms of macrolide resistance in Campylobacter jejuni.
AID103665The anti-mycoplasmal activity was determined against Mycoplasma gallisepticum K514 without the addition of copper1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Synthesis and copper-dependent antimycoplasmal activity of 1-amino-3-(2-pyridyl)isoquinoline derivatives. 2. Amidines.
AID261794Antibacterial activity against Staphylococcus epidermidis ATCC 122282006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.
AID143566Antimycoplasmal activity against Mycoplasma gallisepticum K514 without the extra addition of copper1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Synthesis and copper-dependent antimycoplasmal activity of 1-amino-3-(2-pyridyl)isoquinoline derivatives. 1. Amides.
AID207308Antibacterial activity against Staphylococcus aureus PSCB-03312004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Semisynthetic macrolide antibacterials derived from tylosin. Synthesis and structure-activity relationships of novel desmycosin analogues.
AID523010Activity at macrolide 2'-phosphotransferase 1 by PK/LDH-coupled assay2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
Nucleotide selectivity of antibiotic kinases.
AID518965Induction of erm(C) expression in Escherichia coli JM109 harboring Staphylococcus aureus erm(C)-containing pERMZalpha reporter plasmid at 10 mg/ml after 36 hrs at 37 degC by disc-based beta-galactosidase reporter gene assay2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Induction of erm(C) expression by noninducing antibiotics.
AID261793Antibacterial activity against Staphylococcus aureus ATCC 292132006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.
AID157250In vitro antimicrobial activity against anaerobic bacteria peptococcus prevoti 12811988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID51000In vitro antimicrobial activity against anaerobic bacteria clostridium perfringens 81,1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID208123In vitro antimicrobial activity against Streptococcus pneumoniae1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID207252In vitro antibacterial activity against erythromycin susceptible Staphylococcus aureus 259232004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and antibacterial activity of a novel class of 4'-substituted 16-membered ring macrolides derived from tylosin.
AID208004In vitro antimicrobial activity against aerobic bacteria Streptococcus viridans 99431988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID1873946Antibacterial activity against Staphylococcus aureus ATCC 29213 at pH 8.6 incubated for 16 to 20 hrs in presence of 10% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID209095Effective dose against Streptococcus pyogenes C203 when administered sc1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID1873911Antibacterial activity against Streptococcus dysgalactiae incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID520733Antimicrobial activity against Staphylococcus aureus RN4220 harboring plasmid MS2 by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors.
AID127949Peripheral plasma levels in mice after oral administration of 50 mg/kg dose for 0.25 hr; No detectable concentration of antibiotic1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID571499Antimicrobial activity against Campylobacter jejuni DC2 infected in 15 days old chicken food on medicated food by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Development, stability, and molecular mechanisms of macrolide resistance in Campylobacter jejuni.
AID1873896Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs using 10^5 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID206103In vitro antimicrobial activity against aerobic bacteria Streptococcus D 20411988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID529873Antimicrobial activity against Staphylococcus aureus RN4220 harboring pAT392 containing mph(B) and rdmC-like genes by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene.
AID571497Antimicrobial activity against Campylobacter jejuni DC26 infected in chicken assessed as microbial shedding level after compound administration through feed for 20 days2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Development, stability, and molecular mechanisms of macrolide resistance in Campylobacter jejuni.
AID1873901Antibacterial activity against Staphylococcus aureus ATCC 29213 at pH 8.6 incubated for 16 to 20 hrs in presence of 50% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID396000Antimicrobial activity against Mycoplasma putrefaciens French isolates after 24 hrs by twofold serial dilution method2007Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9
In vitro susceptibilities of Mycoplasma putrefaciens field isolates.
AID510559Antibacterial activity against Escherichia coli AG102MB2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID206934In vitro antimicrobial activity against aerobic bacteria Staphylococcus aureus X4001988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID261789Antibacterial activity against macrolide resistant Staphylococcus aureus ATCC 335912006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.
AID520741Antimicrobial activity against cfr-deficient Staphylococcus aureus RN4220 harboring erm(B) gene by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors.
AID261784Antibacterial activity against macrolide resistant Streptococcus pneumoniae ATCC 7006772006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.
AID174482Peripheral plasma levels in rats after oral administration of 100 mg/kg dose for 2 hr; No detectable concentration of antibiotic1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID1873941Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs in presence of 10% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID571503Antimicrobial activity against Campylobacter jejuni DC6 infected in 3 days old chicken by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Development, stability, and molecular mechanisms of macrolide resistance in Campylobacter jejuni.
AID41412In vitro antimicrobial activity against anaerobic bacteria bacteroides melaninogenicus 27361988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID210412In vitro antimicrobial activity against aerobic bacteria Streptococcus sanguis MX1321988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID1873897Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs using 10^3 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID207689Minimum inhibitory concentration (MIC) required to inhibit the growth of Staphylococcus aureus FDA 209P by using nutrient agar as growth medium1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Novel dimeric derivatives of leucomycins and tylosin, sixteen-membered macrolides.
AID206105In vitro antimicrobial activity against aerobic bacteria Streptococcus D 99601988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID261792Antibacterial activity against macrolide resistant Staphylococcus aureus ATCC BAA-442006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.
AID1424059Induction of ribosome stalling assessed as induction of stalling of ribosome at ermBL ORF at 50 uM by extension inhibition assay2017Journal of natural products, 04-28, Volume: 80, Issue:4
The Berkeleylactones, Antibiotic Macrolides from Fungal Coculture.
AID41266In vitro antimicrobial activity against anaerobic bacteria bacteroides fragilis 18771988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID208779In vitro antibacterial activity against macrolide-lincosamide-streptogramin resistant Streptococcus pneumoniae 7009042004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and antibacterial activity of a novel class of 4'-substituted 16-membered ring macrolides derived from tylosin.
AID127951Peripheral plasma levels in mice after oral administration of 50 mg/kg dose for 0.5 hr; No detectable concentration of antibiotic1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID160384In vitro antimicrobial activity against anaerobic bacteria propionibacterium acnes 791988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID529869Antimicrobial activity against Escherichia coli AG100A harboring pAT392 containing mph(B) gene by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene.
AID117681Protective dose at which 50% of infected, treated mice survive1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID71029In vitro antimicrobial activity against anaerobic bacteria aerofaciens 12351988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID201560Minimum inhibitory concentration (MIC) required to inhibit the growth of Sarcina lutea PCI 1001 by using nutrient agar as growth medium1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Novel dimeric derivatives of leucomycins and tylosin, sixteen-membered macrolides.
AID143442Antimycoplasmal activity against Mycoplasma gallisepticum K514 with the extra addition of copper (40 uM)1988Journal of medicinal chemistry, Apr, Volume: 31, Issue:4
Synthesis and copper-dependent antimycoplasmal activity of 1-amino-3-(2-pyridyl)isoquinoline derivatives. 1. Amides.
AID529870Antimicrobial activity against Escherichia coli AG100A harboring pAT392 containing mph(B) and rdmC-like genes by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene.
AID205752In vitro antimicrobial activity against Streptococcus epidermidis EPI11988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID205874In vitro antimicrobial activity against aerobic bacteria Streptococcus epi 2701988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID128094Peripheral plasma levels in mice after oral administration of 50 mg/kg dose for 4 hr; No detectable concentration of antibiotic1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID510749Antibacterial activity against Escherichia coli AG102MB harboring pP10-based acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID206106In vitro antimicrobial activity against aerobic bacteria Streptococcus G Kruder1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID261785Antibacterial activity against macrolide resistant Streptococcus pneumoniae ATCC 7009052006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.
AID86123In vitro antimicrobial activity against aerobic bacteria Haemophilus influenzae 4651988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID127941Peripheral plasma levels in mice after oral administration of 100 mg/kg dose for 2 hr; No detectable concentration of antibiotic1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID69198Minimum inhibitory concentration (MIC) required to inhibit the growth of Escherichia coli NIHJ using nutrient agar as growth medium1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Novel dimeric derivatives of leucomycins and tylosin, sixteen-membered macrolides.
AID19662Calculated partition coefficient (clogP)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID375080Binding affinity to ribosome/exit tunnel RNA region2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
Design and implementation of an ribonucleic acid (RNA) directed fragment library.
AID72263In vitro antimicrobial activity against anaerobic bacteria fusobacterium symbiosum 14701988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID529879Antimicrobial activity against Enterococcus faecalis JH2-2 harboring empty vector by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene.
AID83807In vitro antimicrobial activity against aerobic bacteria Haemophilus parainfluenzae 97961988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID69789Antibacterial activity against Escherichia coli ATCC 1259222004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Semisynthetic macrolide antibacterials derived from tylosin. Synthesis and structure-activity relationships of novel desmycosin analogues.
AID206930In vitro antimicrobial activity against aerobic bacteria Staphylococcus aureus 513E1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID1873906Antibacterial activity against Staphylococcus aureus ATCC 25923 incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID208778In vitro antibacterial activity against erythromycin susceptible Streptococcus pneumoniae 496192004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and antibacterial activity of a novel class of 4'-substituted 16-membered ring macrolides derived from tylosin.
AID1873889Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 16 to 20 hrs using 10^6 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID210249In vitro antibacterial activity against efflex resistant Streptococcus pyogenes 13232004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and antibacterial activity of a novel class of 4'-substituted 16-membered ring macrolides derived from tylosin.
AID1873943Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs in presence of 50% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID41110In vitro antimicrobial activity against anaerobic bacteria bacteroides corrodens 18741988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID529871Antimicrobial activity against Staphylococcus aureus RN4220 harboring pAT392 containing rdmC-like gene by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene.
AID213462In vitro antimicrobial activity against anaerobic bacteria usobacterium necrophorum 6054A1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID261787Antibacterial activity against Streptococcus pneumoniae ATCC 496192006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.
AID1873944Antibacterial activity against Staphylococcus aureus ATCC 29213 at pH 8.6 incubated for 16 to 20 hrs in absence of foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID207186Antibacterial activity against Staphylococcus aureus PSCB-03302004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Semisynthetic macrolide antibacterials derived from tylosin. Synthesis and structure-activity relationships of novel desmycosin analogues.
AID23096The negative logarithm of the fraction of neutral molecules1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID1873914Antibacterial activity against Pseudomonas aeruginosa LTP-3 incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID205753In vitro antimicrobial activity against aerobic bacteria Streptococcus epi 2221988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID174474Peripheral plasma levels in rats after oral administration of 100 mg/kg dose for 0.5 hr; No detectable concentration of antibiotic1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID85960Antibacterial activity against Haemophilus influenzae ATCC 492472004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Semisynthetic macrolide antibacterials derived from tylosin. Synthesis and structure-activity relationships of novel desmycosin analogues.
AID206933In vitro antimicrobial activity against aerobic bacteria Staphylococcus aureus V411988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID19403Calculated partition coefficient (logD)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID103661Minimum inhibitory concentration measured against Mycoplasma gallisepticum K514 in the absence of extra copper1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and copper-dependent antimycoplasmal activity of amides and amidines derived from 2-amino-1,10-phenanthroline.
AID41431In vitro antimicrobial activity against anaerobic bacteria bacteroides thetaiotaomicron 14381988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID206102In vitro antimicrobial activity against aerobic bacteria Streptococcus C 241988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID127935Peripheral plasma levels in mice after oral administration of 100 mg/kg dose for 0.5 hr; No detectable concentration of antibiotic1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID1873891Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 16 to 20 hrs using 10^4 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID209723In vitro antimicrobial activity against aerobic bacteria Streptococcus pneumoniae B1-4381988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID41559In vitro antimicrobial activity against anaerobic bacteria bacteroides vulgatus 12111988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID174485Peripheral plasma levels in rats after oral administration of 100 mg/kg dose for 4 hr; No detectable concentration of antibiotic1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID581612Binding affinity to Escherichia coli K-12 70S ribosome Pi complex assessed as inhibition of AcPhe-puromycin synthesis at 5 uM after 2 mins by liquid scintillation counting2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Distinct mode of interaction of a novel ketolide antibiotic that displays enhanced antimicrobial activity.
AID1873907Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID529872Antimicrobial activity against Staphylococcus aureus RN4220 harboring pAT392 containing mph(B) gene by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene.
AID1873895Antibacterial activity against Escherichia coli ATCC 25922 incubated for 16 to 20 hrs using 10^4 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID209267Antibacterial activity against Streptococcus pyogenes PSCB-05452004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Semisynthetic macrolide antibacterials derived from tylosin. Synthesis and structure-activity relationships of novel desmycosin analogues.
AID209108In vivo effective dose against experimental infections in rodent caused by Streptococcus pyogenes C203 when administered orally1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID529868Antimicrobial activity against Escherichia coli AG100A harboring pAT392 containing rdmC-like gene by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene.
AID66920Antibacterial activity against Enterococcus faecalis ATCC 292122004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Semisynthetic macrolide antibacterials derived from tylosin. Synthesis and structure-activity relationships of novel desmycosin analogues.
AID86124In vitro antimicrobial activity against aerobic bacteria Haemophilus influenzae 761988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1873910Antibacterial activity against Enterococcus faecium incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873905Antibacterial activity against Staphylococcus aureus incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID571500Antimicrobial activity against Campylobacter jejuni DC26 infected in 15 days old chicken food on medicated food by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Development, stability, and molecular mechanisms of macrolide resistance in Campylobacter jejuni.
AID210250In vitro antibacterial activity against macrolide-lincosamide-streptogramin resistant Streptococcus pyogenes 29122004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and antibacterial activity of a novel class of 4'-substituted 16-membered ring macrolides derived from tylosin.
AID155915Minimum inhibitory concentration against Pasteurella multocida.1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID283559Antibacterial activity against Escherichia coli AG102MB after 24 hrs2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Substrate competition studies using whole-cell accumulation assays with the major tripartite multidrug efflux pumps of Escherichia coli.
AID206100In vitro antimicrobial activity against aerobic bacteria Streptococcus B 51988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID206932In vitro antimicrobial activity against aerobic bacteria Staphylococcus aureus V140,1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID261781Antibacterial activity against Streptococcus pneumoniae ATCC 63012006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.
AID127938Peripheral plasma levels in mice after oral administration of 100 mg/kg dose for 1 hr; No detectable concentration of antibiotic1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.
AID83797In vitro antibacterial activity against ampicillin resistant Haemophilus influenzae 339292004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and antibacterial activity of a novel class of 4'-substituted 16-membered ring macrolides derived from tylosin.
AID208777In vitro antibacterial activity against efflex resistant Streptococcus pneumoniae 77012004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and antibacterial activity of a novel class of 4'-substituted 16-membered ring macrolides derived from tylosin.
AID510747Antibacterial activity against Escherichia coli AG102MB harboring pSport1-based acrB gene2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Single nucleotide polymorphism analysis of the major tripartite multidrug efflux pump of Escherichia coli: functional conservation in disparate animal reservoirs despite exposure to antimicrobial chemotherapy.
AID210023Antibacterial activity against Streptococcus pneumoniae PSCB-05412004Journal of medicinal chemistry, Jan-15, Volume: 47, Issue:2
Semisynthetic macrolide antibacterials derived from tylosin. Synthesis and structure-activity relationships of novel desmycosin analogues.
AID529866Antimicrobial activity against Streptococcus uberis UCN60 expressing mph(B) and rdmC-like genes by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene.
AID117678Protected dose which protects 50% of challenged mice from death owing to the Pasteurella multocida (59A006) infection1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Repromicin derivatives with potent antibacterial activity against Pasteurella multocida.
AID261790Antibacterial activity against macrolide resistant Staphylococcus aureus ATCC 1415412006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.
AID529878Antimicrobial activity against Staphylococcus aureus RN4220 harboring empty vector by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene.
AID529876Antimicrobial activity against Enterococcus faecalis JH2-2 harboring pAT392 containing mph(B) and rdmC-like gene by broth microdilution method2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Emergence of macrolide resistance gene mph(B) in Streptococcus uberis and cooperative effects with rdmC-like gene.
AID520736Antimicrobial activity against erm(B) and cfr-deficient Staphylococcus aureus RN4220 harboring plasmid LI50 by disk diffusion assay2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors.
AID19425HPLC capacity factor (k)1997Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9
Quantitative structure-activity relationships among macrolide antibacterial agents: in vitro and in vivo potency against Pasteurella multocida.
AID520734Antimicrobial activity against methicillin-resistant Staphylococcus aureus CM05 by broth microdilution method2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors.
AID1873947Antibacterial activity against Staphylococcus aureus ATCC 29213 at pH 8.6 incubated for 16 to 20 hrs in presence of 25% foetal bovine serum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID278988Antibacterial activity against Pseudomonas sp. B13 GFP12007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Novel macrolide resistance module carried by the IncP-1beta resistance plasmid pRSB111, isolated from a wastewater treatment plant.
AID1873909Antibacterial activity against Klebsiella pneumoniae ATCC 13883 incubated for 16 to 20 hrs by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID1873890Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 16 to 20 hrs using 10^5 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID93872Minimum inhibitory concentration (MIC) required to inhibit the growth of Klebsiella pneumoniae PCI 602 using nutrient agar as growth medium1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Novel dimeric derivatives of leucomycins and tylosin, sixteen-membered macrolides.
AID1873888Antibacterial activity against Staphylococcus aureus ATCC 29213 incubated for 16 to 20 hrs using 10^7 CFU/ml bacterial inoculum by broth microdilution method2022European journal of medicinal chemistry, Aug-05, Volume: 238Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.
AID261782Antibacterial activity against Streptococcus pneumoniae ATCC 7006712006Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
Synthesis and in vitro antibiotic activity of 16-membered 9-O-arylalkyloxime macrolides.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,033)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990117 (11.33)18.7374
1990's200 (19.36)18.2507
2000's310 (30.01)29.6817
2010's283 (27.40)24.3611
2020's123 (11.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.42 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.94 (4.65)
Search Engine Demand Index146.25 (26.88)
Search Engine Supply Index3.30 (0.95)

This Compound (56.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials107 (9.88%)5.53%
Reviews1 (3.57%)6.00%
Reviews19 (1.75%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies15 (1.39%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other27 (96.43%)84.16%
Other942 (86.98%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]